{"id":"W3029536828","doi":"10.1200/jco.2020.38.15_suppl.tps8553","title":"Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Carfilzomib; Adverse effect; Internal medicine; Dexamethasone; Multiple myeloma; Population; Randomization; Oncology; Clinical trial; Lenalidomide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001554548,0.001521115,0.002343004,0.0002909784,0.0004782517,0.0009234362,0.000569755,0.001221786,0.004310341],"category_scores_gemma":[0.0008200097,0.0007392605,0.001743729,0.0003521875,0.0006591275,0.0007849224,0.0003885077,0.00191411,0.0009475409],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006201649,"about_ca_system_score_gemma":0.001187496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007569297,"about_ca_topic_score_gemma":0.001445644,"domain_scores_codex":[0.9996314,0.0001568987,0.0000252597,0.00008102072,0.00003564302,0.00006976914],"domain_scores_gemma":[0.9993687,0.00009790225,0.0001476227,0.00003266936,0.00002985566,0.0003232006],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9120911,0.02746664,0.01289941,0.0005891219,0.001523805,0.0002515882,0.0001017282,0.0005740746,0.009371802,0.00009143169,0.001542932,0.03349624],"study_design_scores_gemma":[0.7926959,0.1902237,0.01393046,0.00002686809,0.0005544928,0.0001844453,0.00002610784,0.0004662252,0.0004800635,0.00005953368,0.001338133,0.00001415873],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936831,0.002219099,0.0002515537,0.0004013956,0.0001971416,0.002016169,0.0004939628,0.00005131757,0.0006862077],"genre_scores_gemma":[0.9894935,0.001927025,0.001053502,0.001462907,0.0004568329,0.00268444,0.001194362,0.00001578631,0.001711628],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004310341,"threshold_uncertainty_score":0.0144195,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05597045505588093,"score_gpt":0.4017291665442198,"score_spread":0.3457587114883388,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}